International Journal of Clinical Biochemistry and Research

Print ISSN: 2394-6369

Online ISSN: 2394-6377

CODEN : IJCBK6

International Journal of Clinical Biochemistry and Research (IJCBR) open access, peer-reviewed quarterly journal publishing since 2014 and is published under auspices of the Innovative Education and Scientific Research Foundation (IESRF), aim to uplift researchers, scholars, academicians, and professionals in all academic and scientific disciplines. IESRF is dedicated to the transfer of technology and research by publishing scientific journals, research content, providing professional’s membership, and conducting conferences, seminars, and award more...

  • Article highlights
  • Article tables
  • Article images

Article statistics

Viewed: 688

PDF Downloaded: 498


Get Permission Dere, Djoupo, Menin, Coulibaly, and Tiahou: Insulin resistance and dysglycaemia in polycystic ovary syndrome patients


Introduction

Polycystic ovary syndrome (PCOS) is one of the most common endocrinopathy occurring during women reproductive age. It’s characterized by clinical manifestation; such as oligo/anovulation, morphological abnormalities on ovaries and biochemical hyperandrogenism. PCOS affects 5% to 10% women of reproductive age.1 PCOS is marked by a large range of metabolic disorders and abnormalities including hyperinsulinaemia, hyperglycaemia, glucose intolerance, dyslipidaemia, and obesity, which are regarded as the hallmark components of metabolic syndrome (MetS).2 The primmum movens of these abnormalities seems to be due to insulin resistance (IR) which affects the health of PCOS patients and plunges them into type 2 diabetes mellitus ( T2DM). This state is in link with defected lipid profile and exposing patients to metabolic syndrome

(MetS). It is estimated that 70% of women with PCOS have at least one abnormal lipid constituent.3 Among PCOS patients, those who are overweight or obese are more inclined to lipid disorders particularly elevated triacylglycerols (TG) and decreased high-density lipoprotein cholesterol (HDL-C).4 Thus, some studies highlighted the impact of weight on the level of HDL-C in PCOS women.5

MetS is a commun metabolic state found in obesity and PCOS and resulting from many disorders precisely insulin resistance. IR also represents a commun metabolic disorder prevalent in PCOS and obesity. Moreover, accumulating evidence indicates that women with MetS also exhibit hyperandrogenism, contributor to PCOS aetiology. Androgen in excess appears to affect independently the cardiometabolic aberrations in PCOS women.6

Our countries located in south-sahara, aren’t in rest and particularly Côte d’Ivoire which facing a prevalence more and more important of obesity together with other metabolic disorders and endocrinopathy such as PCOS. PCOS known as a most frequent endocrinopathy women undergo is surely endemic in my country. However, too few data of literature are available and this hinders the process in order to better understand and treat PCOS patients. We are to launch into this axis and through this study, we hope to deem the prevalence of insulin resistant within a PCOS patients living in the centre of Côte d’Ivoire and on other side to establish the link between insulin resistant and body mass index (BMI).

Materials and Methods

Population

This cross-sectional study was conducted in 2016 in Bouaké Teaching Hospital. Seventy-one patients diagnosed with PCOS were recruited in this study. The research protocol was approved by the medical and scientific Director of the hospital. Written informed consent was obtained from all participants. The diagnosis of PCOS was confirmed according to the revised Rotterdam criteria,7 in which the presence of any two out of the three following criteria was required and exclusion of other aetiologies.

Any patients with a disease affecting metabolic parameters, including diabetes mellitus, thyroid disorders, and hypertension, were excluded from the study. Patients taking a month before the onset of the study were also excluded. Moreover, history of being on a special diet, such as weight-losing diet during the 3 months before the onset of the study, was regarded an exclusion criterion.

The obtained data for medical history included social and anthropometric parameters. Subjects were weighed in light clothing without shoes. Height was measured to the nearest 0.1 cm, using a wall-mounted stadiometer. BMI was calculated as weight (kg) divided by the square of height (m).8

Laboratory measurements

After a 12-hour overnight fasting, 5 ml blood was obtained in the follicular phase of the menstrual cycle To explore the levels of hormonal parameters including progesterone, estradiol, LH, FSH and so on.9 In terms of high progesterone level, the whole measurements were repeated after one or two week(s) for those that diagnosed PCOS patients we carried out exploration after one or two week(s) for exploring glucose metabolism through static measurement (fasting glucose and fasting insulin) and after oral glucose tolerance test (OGTT). The whole blood samples were centrifuged at 3,000 rpm for 5 minutes. The samples were analyzed either immediately or during the first week after conservation at -20 °C. The serum glucose was analyzed using the standard enzymatic method. Levels of Testosterone, LH, FSH and plasma Insulin levels were all measured using measured using enzyme-linked immune-sorbent assays (ELISAs) method.

Oral Glucose Tolerance Test (OGTT) / evaluation of IR

The standard oral glucose tolerance test (OGTT) was performed another day, after diagnosis, and after withdrawing a blood for fasting glucose and insulin. According to the protocol, we administered 75g of oral glucose for all patients9 and different prelevements were made at T30, T60, T90 and T120 for both glyceamia and insulinemia. The homeostasis model of insulin resistance (HOMA-IR) was calculated as (fasting plasma glucose concentration (mmol/L) × fasting serum insulin concentration (μU/mL)/22.5). IR was defined as HOMA-IR value of ≥3.8.9 Impaired glucose tolerance (IGT) was defined as an elevated fasting glucose (110 mg/ dL ≤G0 ≤125mg/dL) or an elevated 2-hour glucose (140 mg/dL ≤G120 ≤199mg/dL). The patients were divided into insulin-resistant (IR) and insulin-sensitive (IS) groups. Firstly, variations of BMI and hormonal parameters were compared between the two groups, and then, the correlation of glucose profile with insulinemia into different subgroups was analyzed.

Statistical analysis

All the results were tabulated as mean and standard deviation. We used the SPSS 20.0 version for statis­tical analysis. The unpaired student t test was used to determine the statistical significance between the study groups. Pearson correlation was used for cor­relating different parameters. A P value of ˂ 0.05 was considered to be statistically significant.

Ethical considerations

The study was approved by the Institutional Ethics Com­mittee, Medical and Scientific Direction, teaching hospital of Bouaké, Côte d’Ivoire. Written and informed consent was obtained from the indi­viduals who have participated in the study.

Results

The mean age of participants was 25.37 years old and regarding BMI of 28.82 Kg/m2 that was higher than 24.99, the target value of normal BMI. The measurement of biological parameters gave the following means: LH (8.27 mlU/L) ; FSH (5.12 mlU/L) ; testosterone (0.58 nmol/L) and estradiol (49.90 pg/ml). PCOS patients underwent the oral glucose tolerance test during two hours within the peak of serum glucose and insulin reached at T30 with respective values estimated to 7.39 mmol/L and 77.03UI/L (Table 1).

Table 1

Quantitative values of certain parameters explored in PCOS patients.

Min.

Mean

S.D

Max

Age (yrs)

15

25,37

5,47

41

Weight (Kg)

40,0

77,82

22,24

123,0

Height (m)

1,26

1,64

0,08

1,80

BMI (Kg/m2)

15,0

28,82

8,51

46,68

Testosterone (nmol/L)

0,12

0,58

0,26

1,50

LH ( mlU/L)

0,56

8,27

5,07

25,0

FSH ( mlU/L)

1,30

5,12

1,60

8,50

Estradiol (pg/ml)

12,0

49,90

47,37

227,0

Fasting glycaemia (mmol/l)

3,60

4,76

0,75

9,80

Fasting insulinemia (UI/L)

0,53

10,43

8,67

42,0

Glycaemia T30 (mmol/l)

4,40

7,39

1,59

10,90

Insulinemia T30 (UI/L)

0,73

77,03

61,88

298,0

Glycaemia T 60 (mmol/l)

3,10

6,93

2,41

12,1

Insulinemia T60 (UI/L)

1,20

72,73

74,66

462,0

Glycaemia T90 (mmol/l)

2,20

5,97

2,18

12,30

Insulinemia T90 (UI/L)

2,60

59,66

71,35

500,0

Glycaemia T120 (mmol/l)

2,70

5,53

1,59

10,40

Insulinemia T120 (UI/L)

4,30

59,16

73,54

422,0

Table 2

Mean values of Age, anthropometric and hormonal parameters in two different groups

HOMA Insulin resistant group n= 12 (17%)

HOMA Insulin sensitive group n= 59 (83%)

Mean ±SD

Min.

Max.

P

Mean ±SD

Min.

Max.

P

Age

25.50±5.64

15

37

0.888

25.32±5.46

15

41

0.658

BMI (kg/m2)

34.86±6.17

24.80

46.68

0.606

27.59±8.42

15

46

0.000*

Testosterone (nmol/L)

0.76±0.36

0.15

1.50

0.795

0.55±0.21

0.12

1.10

0.835

Estradiol (pg/ml)

35.91±13.47

13.00

56.00

0.929

52.77±51.23

12

227

0.857

LH (mlU/L)

8.66±3.12

3.90

12.00

0.032*

8.22±5.41

0.56

25

0.838

FSH (mlU/L)

4.86±1.10

3.70

7.60

0.280

5.11±1.74

1.30

8.50

0.935

Table 3

Values of glycemia and insulinemia regarding BMI during oral glucose tolerance test (OGTT) in two different groups.

HOMA Insulin-resistant group

HOMA Insulin-sensitive group

Normal BMI

N = 01 (03.45%)

N = 28 (96.55%)

Glycaemia

Insulinemia

Glycaemia

Insulinemia

Go

04.20

Io

21.00

Go

04.65

Io

05.27

P= 0.623

P= 0.001*

G30

05.10

I30

20.00

G30

07.56

I30

36.15

P= 0.824

P= 0.390

G60

03.80

I60

14.40

G60

06.28

I60

49.87

P= 0.780

P= 0.875

G90

03.80

I90

16.00

G90

05.69

I90

30.74

P= 0.101

P= 0.025*

G120

04.50

I120

30.00

G120

06.15

I120

33.52

P= 0.108

P= 0.036*

High BMI (overweight and obese)

N = 11 (26.20%)

N = 31 (73.80%)

Glycaemia

Insulinemia

Glycaemia

Insulinemia

Go

05.34

Io

24.81

Go

04.71

Io

08.66

P= 0.027 *

P= 0.370

P= 0.157

P= 0.377

G30

08.01

I30

111.6

G30

07.47

I30

72.02

P= 0.827

P= 0.296

P= 0.620

P= 0.561

G60

07.34

I60

155.2

G60

07.48

I60

61.68

P= 0.538

P= 0.828

P= 0.740

P= 0.451

G90

09.00

I90

139.3

G90

06.80

I90

56.38

P= 0.432

P= 0.751

P= 0.745

P= 0.514

G120

21.54

I120

123.9

G120

06.23

I120

56.74

P= 0.343

P= 0.738

P= 0.308

P= 0.352

We also noted that 17% of PCOS patients have got a HOMA Insulin Resistant in contrary to 83% of patients with a HOMA insulin sensitive state. Obesity was significantly more prevalent in the IR group compared to the IS group. PCOS patients HOMA IR group had a mean BMI significantly higher than those of IS group (Table 2). Otherwise, the mean values of testosterone and LH were higher in the IR group as opposed to those of estradiol and FSH higher in the IS group. Thus, the ratio of LH/FSH (1.78) was higher in the IR group (Table 2).

Out of 12 insulin-resistant PCOS patients, only 01 had normal BMI and 11 were overweight or obese (91.70%) contrary to those in insulin-sensitive group within 47.45% had normal BMI and 52.54% were overweight or obese. In the subgroup of IR with high BMI, we noticed the higher values of glycemia precisely fasting, T30, T90 and T120. The rate of dysglycemia was more predominant in this subgroup following by the subgroup of IS with high BMI patients. The ratio of fasting glucose/ fasting insulin was lower in the HOMA obese group with values under 0.21 at T0 and a minimal value of 0.04 found at T60 (Table 3).

Discussion

HOMA-estimated insulin resistance is an independent predictor of cardiovascular disease in T2DM subjects but also for patients suffering from other endocrinopathy such as PCOS or metabolic diseases. Previous studies have indicated that insulin resistance plays an important role in the pathogenesis of polycystic ovary syndrome.10 Insulin would act synergistically with luteinizing hormone (LH), leading to increased production of androgens in the ovarian theca cells.11 Wehr et al.12 have reported that increased serum testosterone levels in PCOS women are associated with excess of visceral fat amount, insulin resistance and more frequent occurrence of impaired glucose tolerance. IR would be one of the most prevalent metabolic perturbations in women with PCOS, affecting 65-70% of all patients.13 As a consequence of the perturbed insulin action, a higher amount of insulin is required to attain its metabolic effects, which results in increased production and release of insulin from pancreatic β cells. This is why IR is frequently associated with compensatory hyperinsulinemia.13, 14, 15

In our cohort, the degree of insulin resistance was estimated at the baseline by HOMA according to the method described by Matthews et al.6 In our trial, 17% of recruited PCOS patients displayed a case of HOMA-IR. In our cohort, the mean age and BMI was estimated at 25.37±5.47 years and 28.82kg/m2, however, the value of BMI were widely lower to those of HOMA-IR. Indeed that argues metabolic disorders resulting from weight gaining and fat accumulating in adiposity cells before PCOS occurring. Our results were slightly lower than those reported by Ebrahimi-M. et al.16 respectively of 26.9±5.7 years and 31.4±3.8 kg/m2; in a study focused on association of insulin resistance in overweight or obese women with PCOS. Related to BMI, this discrepancy could be due to the criteria of recruitment focused on overweight and obese PCOS patients in their study.

Within PCOS patients with HOMA IR, the mean age was higher (25.50±5.64 years) together with BMI which was at 34.86±6.17 kg/m2 by opposite to IS group with respectively 25.32±5.46 years and 27.59±8.42 kg/m2. Thus, IR was more prevalent to PCOS patients more aged and presenting a higher value of BMI. This trend was in line with the report of literature.11, 14 Thus HOMA-IR was significantly correlated with age, BMI, fasting glucose and fasting insulin. Clinical studies documented that women with PCOS showed increased global adiposity17 and thickness of the intraperitoneal and mesenteric fat compared with control women.18 However, the molecular mechanisms implicated in the increased abdominal adiposity induced by chronic exposure to androgens remain partially known and could be due to the hypersecretion of LH. To elucidate this point, a preclinical study of female mice conducted by Nohara et al.19 has been done. They suggested that androgen excess may perturb the ability of leptin to stimulate energy expenditure, which in turn may promote visceral fat accumulation.

Our results corroborate the findings reported by Sanchez et al.14 who found that the mean BMI and the prevalence of obesity were higher in the IR compared to the IS patients. In fact, abdominal obesity may result in higher insulin concentration.20 Although unsteadily, IR occurs in obese as well as lean subjects with PCOS,21 any degree of obesity is liable to trigger reduced insulin sensitivity. In non diabetic as well as diabetic subjects, insulin resistance is related to several cardiovascular risk factors, including hyperglycemia, dyslipidemia, hypertension, etc. Previous studies22, 23, 24 confirmed that metabolic abnormalities are less severe in normoandrogenic women with PCOS in comparison to phenotypes with hyperandrogenism.

Consequently, insulin resistance might be regarded as an important factor in the pathogenesis of cardiovascular disease (CVD) in type 2 diabetes. Nonetheless, it is interesting to establish whether insulin resistance does contribute to atherosclerosis or cardiovascular disease. That evidence would be of great clinical value, because it might strongly justify and encourage the use of therapeutic options, including drugs able to improve insulin sensitivity, with the aim of reducing the cardiovascular risk. Standing the role of hyperinsulinemia as a pathogenic factor for the development of hyperandrogenism and PCOS, a variety of studies demonstrated that intervention with oral diabetic drugs such as metformin or thiazolidinediones (TZDs) reduces circulating insulin and androgen levels, increases SHBG levels, and improves ovarian function in women with PCOS.25, 26, 27

Our results related to glucose metabolism in link with OGTT showed that the mean values of fasting glucose among different subgroups were normal. Nonetheless, based on the value after two hours, we noticed in the HOMA IR with high BMI subgroup that the serum glucose was at 21.54 mmol/l; outlined glucose intolerance and also insulin resistance. This fact reveals a disturbance in serum glucose regulation which could rise as this pathology growing up. As previously outlined, women with PCOS frequently exhibit insulin resistance associated to hyperinsulinemia and a high propensity for developing Type 2 Diabetes. While the effect of androgen excess on systemic insulin sensitivity has been extensively explored, less attention has been paid to assessing the impact of hyperandrogenism on β cell function and insulin release. However, some evidence suggests that androgen excess may contribute to impairing glucose tolerance and β cell function in women with PCOS.28, 29 However, the mechanisms underpinning this androgenic effect on the pancreas remain poorly understood.

The higher value of serum glucose has been observed at the 30th minutes after oral glucose tolerance test (7.39 mmol/L). The peak of glycemia also aroused an important secretion of insulin which reached a value of 77.03 UI/l. This trend has also been registered for both subgroup namely for HOMA IR group and HOMA IS group. Nonetheless, the most important peak has been observed in the HOMA IR with high BMI group.

Consequently, all environmental factors that can lead to overweight or obesity and alter insulin action may be involved in the etiology of this endocrine disorder. Diet and lifestyle are the main factors that may cause or exacerbate the metabolic and reproductive abnormalities of PCOS.30 Sedentary lifestyle and inadequate dietary habits may promote obesity and insulin resistance and contribute to worsening the metabolic and reproductive features of PCOS. Supporting the role of these environmental elements in the pathogenesis of PCOS, it has been documented that an improvement in insulin sensitivity through lifestyle and diet modifications is sufficient to ameliorate some indexes of reproductive perturbations in obese women with PCOS such as anovulation and menstrual cycle irregularities.31, 32

One limitation of the present study is a relatively small number of participants representing different PCOS phenotypes. Another limitation is the use of HOMA-IR to estimate insulin resistance. The gold standard in the assessment of the whole-body insulin sensitivity is hyperinsulinemic euglycemic clamp; however, it is time-consuming and difficult to perform.33

Conclusion

The rate of PCOS patients with HOMA-IR was important and was correlated to anthropometric disorders and high level of LH and testosterone. This clinical state is the cornerstone of metabolic disorders namely dysglycaemia which leads to type 2 diabetes. To facing this important endocrinopathy and handling its isssue, It's strongly advised to early diagnosed PCOS in order to adopt the necessary actions to treat and prevent weigh gaining, primum movens of disturbances registered. It'll be advisable to implement such study within different study groups in accordance with our lifestyle to appreciate the real impact of insulin resistance in our population and act upstream to prevent/reduce metabolic diseases.

Source of Funding

None.

Conflict of Interest

The authors declare that there is no conflict of interest.

References

1 

BO Yildiz G Bozdag Z Yapici I Esinler H Yarali Prevalence, phenotype and cardiometabolic risk of polycystic ovary syndrome under different diagnostic criteriaHum Reprod2012271030677310.1093/humrep/des232

2 

ED Kandarakis A Dunaif Insulin Resistance and the Polycystic Ovary Syndrome Revisited: An Update on Mechanisms and ImplicationsEndocr Rev2012336981103010.1210/er.2011-1034

3 

DA Ehrmann Genetic contributions to glucose intolerance in polycystic ovary syndromeReprod BioMed Online200491283410.1016/s1472-6483(10)62106-2

4 

E Wehr R Möller R Horejsi A Giuliani D Kopera N Schweighofer Subcutaneous adipose tissue topography and metabolic disturbances in polycystic ovary syndromeWiener klinische Wochenschrift20091217-8262910.1007/s00508-009-1162-2

5 

NM Clark AJ Podolski ED Brooks DR Chizen RA Pierson DC Lehotay Prevalence of Polycystic Ovary Syndrome Phenotypes Using Updated Criteria for Polycystic Ovarian Morphology: An Assessment of Over 100 Consecutive Women Self-reporting Features of Polycystic Ovary SyndromeReprod Sci201421103443

6 

DR Matthews JP Hosker AS Rudenski BA Naylor DF Treacher RC Turner Homeostasis model assessment: insulin resistance and ?-cell function from fasting plasma glucose and insulin concentrations in manDiabetologia1985287412910.1007/bf00280883

7 

A Dunaif Insulin resistance and the polycystic ovary syndrome: Mechanism and implications for pathogenesisEndocr Rev199718774800

8 

A Mari G Pacini AR Brazzale B Ahren Comparative evaluation of simple insulin sensitivity methods based on the oral glucose tolerance testDiabetologia20054847485110.1007/s00125-005-1683-9

9 

M Matsuda RA Defronzo Insulin sensitivity indices obtained from oral glucose tolerance testing: comparison with the euglycemic insulin clampDiabetes Care1999229146270

10 

R Azziz E Carmina D Dewailly E Diamanti-Kandarakis HF Escobar-Morreale W Futterweit Positions statement: Criteria for defining polycystic ovary syndrome as a predominantly hyperandrogenic syndrome: An Androgen Excess Society guidelineJ. Clin. Endocrinol. Metab200691423745

11 

AM Polak A Adamska A Krentowska A Łebkowska J Hryniewicka M Adamski Body Composition, Serum Concentrations of Androgens and Insulin Resistance in Different Polycystic Ovary Syndrome PhenotypesJ Clin Med20209373210.3390/jcm9030732

12 

E Wehr R Möller R Horejsi A Giuliani D Kopera N Schweighofer Subcutaneous adipose tissue topography and metabolic disturbances in polycystic ovary syndromeWiener klinische Wochenschrift20091217-8262910.1007/s00508-009-1162-2

13 

JC Marshall A Dunaif Should all women with PCOS be treated for insulin resistance?Fertil Steril2012971182210.1016/j.fertnstert.2011.11.036

14 

MA Sanchez-Garrido M Tena-Sempere Metabolic dysfunction in polycystic ovary syndrome: Pathogenic role of androgen excess and potential therapeutic strategiesMol Metab20203510093710.1016/j.molmet.2020.01.001

15 

JE Nestler Metformin for the Treatment of the Polycystic Ovary SyndromeNew Engl J Med20083581475410.1056/nejmct0707092

16 

ME Mamaghani M Saghafi-Asl S Pirouzpanah A Aliasgharzadeh S Aliashrafi N Rezayi Association of insulin resistance with lipid profile, metabolic syndrome, and hormonal aberrations in overweight or obese women with polycystic ovary syndromeJ Health Popul Nutr201533115767

17 

DJ Evans JH Barth CW Burke Body fat topography in women with androgen excessInt J Obes198812215762

18 

S Borruel E Fernández-Durán M Alpañés D Martí F Álvarez-Blasco M Luque-Ramírez Global Adiposity and Thickness of Intraperitoneal and Mesenteric Adipose Tissue Depots Are Increased in Women With Polycystic Ovary Syndrome (PCOS)J Clin Endocrinol Metab201398312546310.1210/jc.2012-3698

19 

K Nohara A Laque C Allard H Münzberg FM Jarvis Central mechanisms of adiposity in adult female mice with androgen excessObes201422614778410.1002/oby.20719

20 

L Poretsky On the Paradox of Insulin-Induced Hyperandrogenism in Insulin-Resistant StatesEndocr Rev199112131310.1210/edrv-12-1-3

21 

SR Plymate LA Matej RE Jones KE Friedl Inhibition of Sex Hormone-Binding Globulin Production in the Human Hepatoma (Hep G2) Cell Line by Insulin and Prolactin*J Clin Endocrinol Metab1988673460410.1210/jcem-67-3-460

22 

E Diamanti-Kandarakis A Dunaif Insulin Resistance and the Polycystic Ovary Syndrome Revisited: An Update on Mechanisms and ImplicationsEndocr Rev2012336981103010.1210/er.2011-1034

23 

AS Jamil SK Alalaf NG Al-Tawil T Al-Shawaf Comparison of clinical and hormonal characteristics among four phenotypes of polycystic ovary syndrome based on the Rotterdam criteriaArch Gynecol Obstet201629324475610.1007/s00404-015-3889-5

24 

D Wiltgen PM Spritzer Variation in metabolic and cardiovascular risk in women with different polycystic ovary syndrome phenotypesFertil Steril20109462493610.1016/j.fertnstert.2010.02.015

25 

JE Nestler Metformin for the Treatment of the Polycystic Ovary SyndromeNew Engl J Med20083581475410.1056/nejmct0707092

26 

EM Velazquez S Mendoza T Hamer F Sosa CJ Glueck Metformin therapy in polycystic ovary syndrome reduces hyperinsulinemia, insulin resistance, hyperandrogenemia, and systolic blood pressure, while facilitating normal menses and pregnancyMetab19944356475410.1016/0026-0495(94)90209-7

27 

N Nathan S Sullivan The Utility of Metformin Therapy in Reproductive-Aged Women with Polycystic Ovary Syndrome (PCOS)Current Pharm Biotechnol2014151708310.2174/1389201015666140330195142

28 

B Zhang J Wang S Shen J Liu J Sun T Gu Association of androgen excess with glucose intolerance in women with polycystic ovary syndromeBiomed Res Int201810.1155/2018/6869705

29 

W Xu J Morford FM Jarvis Emerging role of testosterone in pancreatic β cell function and insulin secretionJ Endocrinol20192403R97R10510.1530/joe-18-0573

30 

E Diamanti-Kandarakis H Kandarakis RS Legro The Role of Genes and Environment in the Etiology of PCOSEndocr2006301192610.1385/endo:30:1:19

31 

M.-M. Huber-Buchholz Restoration of Reproductive Potential by Lifestyle Modification in Obese Polycystic Ovary Syndrome: Role of Insulin Sensitivity and Luteinizing HormoneJ Clin Endocrinol Metab19998441470410.1210/jc.84.4.1470

32 

DS Kiddy D Hamilton-Fairley A Bush F Short V Anyaoku MJ Reed Improvement in endocrine and ovarian function during dietary treatment of obese women with polycystic ovary syndromeClin Endocrinol19923611051110.1111/j.1365-2265.1992.tb02909.x

33 

A Mari G Pacini AR Brazzale B. Ahren Comparative evaluation of simple insulin sensitivity methods based on the oral glucose tolerance testDiabetol20054847485110.1007/s00125-005-1683-9



jats-html.xsl


This is an Open Access (OA) journal, and articles are distributed under the terms of the Creative Commons Attribution-NonCommercial-ShareAlike 4.0 License, which allows others to remix, tweak, and build upon the work non-commercially, as long as appropriate credit is given and the new creations are licensed under the identical terms.

Article type

Original Article


Article page

478-483


Authors Details

Kwadjo Anicet Luc Dere, Agnon Prisca Djoupo, Messou Michèle Menin, Djenebou Coulibaly, Gnomblesson Georges Tiahou


Article Metrics


View Article As

 


Downlaod Files